012

Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: Results From the 52-Week Phase 3 INTEGUMENT-OLE Trial in Patients Aged ≥2 Years

Mark Boguniewicz,[1] H. Chih-ho Hong,[2] Lawrence F. Eichenfield,[3] Alexandra Golant,[4] Adelaide A. Hebert,[5] Amy Paller,[6] April W. Armstrong,[7] Linda Stein Gold,[8] David Krupa,[9] Patrick Burnett,[9] Diane Hanna,[9] Brett Stephenson[9]

[1]National Jewish Health, Denver and University of Colorado School of Medicine, Aurora, CO; [2]University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC; [3]Rady Children's Hospital–San Diego, University of California San Diego School of Medicine, San Diego, CA; [4]Icahn School of Medicine at Mount Sinai, New York, NY; [5]UTHealth McGovern Medical School, Houston, TX; [6]Northwestern University Feinberg School of Medicine, Chicago, IL; [7]David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; [8]Henry Ford Health System, Detroit, MI; [9]Arcutis Biotherapeutics, Inc., Westlake Village, CA

Scan QR code to request a digital copy of this poster be sent to you.

ABBREVIATIONS

AD, atopic dermatitis; AE, adverse event; BIW, twice weekly; BSA, body surface area affected; EASI, Eczema Area and Severity Index; FAS, full analysis set; K-M, Kaplan-Meier; NE, not evaluable; OLE, open-label extension; PDE4, phosphodiesterase 4; QD, once daily; SAE, serious AE; TCI, topical calcineurin inhibitor; TCS, topical corticosteroid; TEAE, treatment-emergent AE; vIGA-AD, Validated Investigator Global Assessment for AD; WI-NRS, Worst Itch Numeric Rating Scale.

REFERENCES

1. Silverberg JI, et al. *Ann Allergy Asthma Immunol*. 2021;126:417–428. 2. Hadi HA, et al. *Life*. 2021;11:936. 3. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel. *Ann Allergy Asthma Immunol*. 2023;132:274–312. 4. Burshtein J, et al. *Dermatol Online J*. 2025;31(1). doi:10.5070/D331164978. 5. Capozza K and Schwartz A. *Pediatr Dermatol*. 2020;37:59–61. 6. Sathishkumar D, et al. *Curr Med Issues*. 2020;18:317–325. 7. Barta K, et al. *Ann Allergy Asthma Immunol*. 2023;130(1):93–99e10. 8. Davis DMR, et al. *J Am Acad Dermatol*. 2025;93(3):745.e1–745.e7. 9. Draelos ZD, et al. *J Drugs Dermatol*. 2024;23:834–840. 10. Simpson EL, et al. *JAMA Dermatol*. 2024;160:1161–1170. 11. Eichenfield LF, et al. *Pediatr Dermatol*. 2025;42:296–304. 12. Simpson EL, et al. *Dermatitis*. Available online January 10, 2025; doi:10.1089/derm.2024.0418.

ACKNOWLEDGMENTS

Thank you to the investigators and their staff for their participation in the trials. We are grateful to the study participants and their families for their time and commitment. Writing support was provided by Kelly M. Fahrbach, PhD, CMPP, and Andrea Michels, of Ashfield MedComms, an Inizio company, and was funded by Arcutis Biotherapeutics, Inc.

DISCLOSURES

This study was funded by Arcutis Biotherapeutics, Inc. HCH, MB, LFE, AG, AAH, AP, AWA, and LSG are investigators and/or consultants for and received grants/research funding and/or honoraria from Arcutis Biotherapeutics, Inc. DK, PB, DH, and BS are employees of Arcutis Biotherapeutics, Inc. Additional disclosures provided upon request.

Presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting; February 27–March 2, 2026; Philadelphia, PA.

INTRODUCTION

- AD is a chronic inflammatory skin disease that is often first diagnosed during childhood and can persist into adulthood[1,2]
- Complicated treatment regimens and limitations to topical therapies that are commonly used (ie, TCS and TCIs) can impact adherence to treatment and prolong signs and symptoms of AD[3–5]
  - Because of increased risk of cutaneous and systemic AEs, TCS are not approved for long-term use and higher potency TCS are not recommended for thin-skinned areas (eg, face, younger skin) where there is greater systemic absorption[3,4,6]
  - Children generally have higher BSA and a higher BSA-to-weight ratio, thus, they are at even greater risk for AEs[6]
  - A burning/stinging sensation at the site of application has been reported with the use of topical crisaborole and TCIs[3]
- Alternative topical treatment options with the potential for proactive, long-term use to maintain disease control are needed[7,8]
- Topical roflumilast, a potent, advanced targeted PDE4 inhibitor, has been formulated as a cream or foam that does not include propylene glycol, formaldehyde, fragrances, or other potential cutaneous irritants[9]
- Efficacy, safety, and tolerability of once-daily roflumilast cream 0.15% and 0.05% in patients with AD aged ≥6 years and 2–5 years, respectively, were demonstrated in the 4-week, phase 3 INTEGUMENT-1/2 (NCT04662487/NCT04773600)[10] and INTEGUMENT-PED (NCT04845620)[11] trials
  - Use of roflumilast cream 0.15% or 0.05% for up to 56 weeks in patients aged ≥2 years with AD was investigated in the INTEGUMENT-OLE (NCT04804605) study
  - Primary safety and efficacy outcomes in patients aged ≥6 years from the OLE study are reported by Simpson, et al[12]
- Long-term outcomes, including changes in BSA, disease clearance, and disease control, of patients who participated in the INTEGUMENT-OLE trial are reported here

METHODS

Study design

- INTEGUMENT-OLE was a 52-week, phase 3, multicenter, OLE trial in patients aged ≥2 years with mild-to-moderate AD
- Patients who completed 4 weeks in one of the parent studies (INTEGUMENT-1/2, ≥6 years [no upper limit] or INTEGUMENT-PED, 2–5 years) with no safety concerns were eligible to enroll in the INTEGUMENT-OLE trial and initiate or continue roflumilast cream 0.15% or 0.05%, respectively, once daily
  - Patients who 'aged up' from 5 to 6 years during the study were switched to roflumilast cream 0.15% at their first scheduled visit after their 6th birthday
- Patients could switch to BIW application any time at/after week 4, if they achieved vIGA-AD clear (0)
  - BIW application was maintained as long as signs and symptoms of AD were adequately controlled and vIGA-AD remained clear or almost clear (0/1)

Assessments in this analysis

- vIGA-AD 0/1
- Mean EASI over time
- Mean WI-NRS over time
- BSA over time
- Rates of disease clearance (ie, vIGA-AD 0) and proportions of patients switching to BIW application
- Duration of 'disease control', defined as vIGA-AD 0/1 and adequate control of signs and symptoms with BIW in patients who had achieved IGA 0 on or after week 4 of INTEGUMENT-OLE
- Safety and application-site tolerability

INTEGUMENT-OLE Study Design



Application of nonmedicated emollients or moisturizers was allowed as a part of the patient's stable regimen

[a]After OLE study enrollment commenced, the protocol was amended to allow patients (aged 2–5 years) who completed INTEGUMENT-PED to enroll, as well as a 24-week cohort consisting of an additional ~550 patients aged 6–17 years. Patients must have completed 4 weeks in a parent trial with no safety concerns. [b]Applied on two nonconsecutive days per week to areas commonly and/or most recently affected by AD, and any areas where AD was developing.

RESULTS

- 562 patients from INTEGUMENT-PED and 658 patients from INTEGUMENT-1/2[12] completed one of these parent studies and enrolled in INTEGUMENT-OLE
  - Mean BSA (at parent-study baseline) for patients entering the OLE, respectively, was 13.9% and 20.8%; ~82% of patients were not Hispanic or Latino and 63%–71% were White
  - Patient demographics and baseline clinical characteristics were balanced among the populations who continued in the OLE study
- Improvements in AD observed in the parent trials were maintained or continued to improve through the end of the OLE study
  - By treatment week 56, vIGA-AD 0/1 was achieved by 63.1% of patients from INTEGUMENT-PED and 55.7% of patients from INTEGUMENT-1/2
  - Mean BSA decreased from baseline of each parent study through the end of the OLE
- Approximately 1/3 patients achieved vIGA-AD 0 at/after OLE week 4 and were eligible to switch to BIW application
  - The majority of patients who achieved vIGA-AD 0 and did not switch to BIW application achieved vIGA-AD 0 at their last study visit and, therefore, were not able to switch to BIW application
- Patients from INTEGUMENT-PED and INTEGUMENT-1/2 who switched to BIW application maintained a median duration of 'disease control' (K-M estimates) of 238 days (34 weeks) and 281 days (>40 weeks),[12] respectively
- Roflumilast cream 0.15% and 0.05% were each well tolerated, as previously reported[10–12]
  - Application-site pain was reported as an AE for 0.7% of patients from INTEGUMENT-PED and 0.5% of patients from INTEGUMENT-1/2[12]

Durable Improvements in AD (vIGA-AD)



FAS; observed data. [a]Patients entering the OLE from INTEGUMENT-PED. [b]Patients entering the OLE from INTEGUMENT-1/2. [c]Treatment week count begins as week 0 at the start of the 4-week parent trial (INTEGUMENT-PED or INTEGUMENT-1/2) and continues through 52 weeks of INTEGUMENT-OLE.

Durable Improvements in AD Severity and Itch Over Time



FAS; observed data; EASI was scored at clinic visits and WI-NRS in an at-home diary by the patient or caregiver. [a]Patients entering the OLE from INTEGUMENT-PED. [b]Patients entering the OLE from INTEGUMENT-1/2. [c]Treatment week count begins as week 0 at the start of the 4-week parent trial (INTEGUMENT-PED or INTEGUMENT-1/2) and continues through 52 weeks of INTEGUMENT-OLE.

BSA Over Time



FAS; observed data. [a]Patients entering the OLE from INTEGUMENT-PED. [b]Patients entering the OLE from INTEGUMENT-1/2. [c]Treatment week count begins as week 0 at the start of the 4-week parent trial (INTEGUMENT-PED or INTEGUMENT-1/2) and continues through 52 weeks of INTEGUMENT-OLE.

'Disease Control' With Proactive BIW Application

	Achieved vIGA-AD 0 at/after OLE week 4		Achieved vIGA-AD 0 and switched to proactive BIW application	Median duration of 'disease control'[c] with BIW application
	Through OLE week 24 (Treatment week 28)	*Through OLE week 52 (Treatment week 56)*		
Aged 2–5 years; roflumilast cream 0.05%[a] (n=562)	26.7% (150 patients)	35.7% (201 patients)	30.2% (170 patients)	238 days (95% CI, 146–331)
Aged ≥6 years; roflumilast cream 0.15%[b] (n=658)	26.1% (172 patients)	31.5% (207 patients)	19.8% (130 patients)	281 days (95% CI, 147–NE)

[a]Patients entering the OLE from INTEGUMENT-PED. [b]Patients entering the OLE from INTEGUMENT-1/2. [c]K-M median.

Safety Summary

Patients, n (%)		Aged 2–5 years; roflumilast cream 0.05%[a] (n=562)	Aged ≥6 years; roflumilast cream 0.15%[b] (n=657)
≥1 TEAE		280 (49.8)	241 (36.7)
≥1 treatment-related AE		14 (2.5)	31 (4.7)
≥1 SAE		18 (3.2)	8 (1.2)
≥1 treatment-related SAE		0	0
≥1 TEAE leading to discontinuation of study/study drug		17 (3.0)/18 (3.2)	20 (3.0)/21 (3.2)
Most common TEAEs by preferred term, ≥4.0% of patients in either group	Upper respiratory tract infection	49 (8.7)	21 (3.2)
	Nasopharyngitis	28 (5.0)	20 (3.0)
	Pyrexia	28 (5.0)	5 (0.8)
	COVID-19	18 (3.2)	30 (4.6)

Safety population. Summary of TEAEs occurring during INTEGUMENT-OLE. [a]Patients entering the OLE from INTEGUMENT-PED. [b]Patients entering the OLE from INTEGUMENT-1/2.

CONCLUSIONS

- Once-daily and proactive BIW roflumilast cream 0.15% and 0.05% decreased signs and symptoms of AD and maintained improvements through up to 56 weeks of treatment in patients aged ≥2 years
- In addition to durable improvements in vIGA-AD, EASI, and itch symptoms (WI-NRS), BSA decreased through 4 weeks of treatment in parent trials, and was maintained or improved further over 52 weeks of treatment in the OLE
- Approximately 1/3 patients achieved clear skin (vIGA-AD 0) with once-daily application
  - Patients from INTEGUMENT-PED and INTEGUMENT-1/2 who achieved clear skin and transitioned to proactive BIW application were able to maintain 'disease control' for a median of 238 and 281 days (K-M estimates), respectively
- Overall, these results indicate that roflumilast cream is well tolerated and an appropriate alternative to topical therapies that are not recommended for long-term continuous use (eg, TCS or TCIs) for patients with AD